AU2013296494B2 - Methods for treatment of atherosclerosis - Google Patents

Methods for treatment of atherosclerosis Download PDF

Info

Publication number
AU2013296494B2
AU2013296494B2 AU2013296494A AU2013296494A AU2013296494B2 AU 2013296494 B2 AU2013296494 B2 AU 2013296494B2 AU 2013296494 A AU2013296494 A AU 2013296494A AU 2013296494 A AU2013296494 A AU 2013296494A AU 2013296494 B2 AU2013296494 B2 AU 2013296494B2
Authority
AU
Australia
Prior art keywords
pct
peptide
statin
simvastatin
atorvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013296494A
Other languages
English (en)
Other versions
AU2013296494A1 (en
Inventor
Marc W. Andersen
Mark BAMBERGER
Brian BLAKEY
D. Travis Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of AU2013296494A1 publication Critical patent/AU2013296494A1/en
Priority to AU2018202197A priority Critical patent/AU2018202197A1/en
Application granted granted Critical
Publication of AU2013296494B2 publication Critical patent/AU2013296494B2/en
Assigned to STEALTH BIOTHERAPEUTICS INC. reassignment STEALTH BIOTHERAPEUTICS INC. Request for Assignment Assignors: STEALTH PEPTIDES INTERNATIONAL, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2013296494A 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis Active AU2013296494B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018202197A AU2018202197A1 (en) 2012-08-02 2018-03-27 Methods for treatment of atherosclerosis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261678992P 2012-08-02 2012-08-02
US61/678,992 2012-08-02
US201261695850P 2012-08-31 2012-08-31
US201261695807P 2012-08-31 2012-08-31
US61/695,850 2012-08-31
US61/695,807 2012-08-31
PCT/US2013/053008 WO2014022552A1 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202197A Division AU2018202197A1 (en) 2012-08-02 2018-03-27 Methods for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
AU2013296494A1 AU2013296494A1 (en) 2015-02-26
AU2013296494B2 true AU2013296494B2 (en) 2018-04-26

Family

ID=50028503

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013296494A Active AU2013296494B2 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis
AU2013296493A Active AU2013296493B2 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis
AU2018202068A Abandoned AU2018202068A1 (en) 2012-08-02 2018-03-23 Methods for treatment of atherosclerosis
AU2018202197A Abandoned AU2018202197A1 (en) 2012-08-02 2018-03-27 Methods for treatment of atherosclerosis

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2013296493A Active AU2013296493B2 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis
AU2018202068A Abandoned AU2018202068A1 (en) 2012-08-02 2018-03-23 Methods for treatment of atherosclerosis
AU2018202197A Abandoned AU2018202197A1 (en) 2012-08-02 2018-03-27 Methods for treatment of atherosclerosis

Country Status (8)

Country Link
US (5) US10188693B2 (cg-RX-API-DMAC7.html)
EP (6) EP3662921A1 (cg-RX-API-DMAC7.html)
JP (5) JP2015529655A (cg-RX-API-DMAC7.html)
CN (3) CN110090304A (cg-RX-API-DMAC7.html)
AU (4) AU2013296494B2 (cg-RX-API-DMAC7.html)
CA (2) CA2880643A1 (cg-RX-API-DMAC7.html)
HK (2) HK1210962A1 (cg-RX-API-DMAC7.html)
WO (2) WO2014022551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
CN110193077A (zh) * 2012-10-22 2019-09-03 康德生物医疗技术公司 降低与心脏衰竭相关的风险和与其相关的因素的方法
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11355245B2 (en) * 2016-05-03 2022-06-07 International Business Machines Corporation Identifying and ranking risk factors using trained predictive models
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
IL322723A (en) 2017-04-05 2025-10-01 Stealth Biotherapeutics Inc Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202005439D0 (en) 2020-04-14 2020-05-27 Aurigen Medical Ltd A device for occlusion of a left a trial appendage of a heart

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001023A2 (en) * 2003-05-01 2005-01-06 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
CA2455336A1 (en) 2001-08-10 2003-02-20 Novartis Ag Peptides that bind to atherosclerotic lesions
PT1599216E (pt) * 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
JP2009525281A (ja) * 2006-01-30 2009-07-09 イスラエル ベン デビッド ブライソン、 心臓血管系疾患、脳血管系疾患および他の血管系疾患の患者を治療するための組成物ならびに方法
JP4881385B2 (ja) 2006-08-30 2012-02-22 国立大学法人九州大学 スタチン封入ナノ粒子含有医薬組成物
WO2009092071A2 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
DK2252312T3 (da) * 2008-02-07 2014-06-16 Univ Cornell Fremgangsmåder til forebyggelse eller behandling af insulinresistens
JP5909182B2 (ja) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
EP3040080A1 (en) * 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001023A2 (en) * 2003-05-01 2005-01-06 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Also Published As

Publication number Publication date
US10188693B2 (en) 2019-01-29
AU2013296494A1 (en) 2015-02-26
EP2879688A4 (en) 2015-12-16
EP2879689A1 (en) 2015-06-10
US20180344797A1 (en) 2018-12-06
JP2015524439A (ja) 2015-08-24
HK1210962A1 (en) 2016-05-13
US20180339012A1 (en) 2018-11-29
AU2018202197A1 (en) 2018-04-26
JP2019108389A (ja) 2019-07-04
AU2018202068A1 (en) 2018-04-19
EP2879688A1 (en) 2015-06-10
EP3485897A1 (en) 2019-05-22
JP2018012726A (ja) 2018-01-25
WO2014022551A1 (en) 2014-02-06
AU2013296493A1 (en) 2015-02-26
AU2013296493B2 (en) 2018-04-26
JP2015529655A (ja) 2015-10-08
HK1210953A1 (en) 2016-05-13
CN104661670A (zh) 2015-05-27
EP3662921A1 (en) 2020-06-10
CN104768564A (zh) 2015-07-08
EP3300740A1 (en) 2018-04-04
JP2018016637A (ja) 2018-02-01
EP2879689A4 (en) 2015-12-16
CA2880648A1 (en) 2014-02-06
CA2880643A1 (en) 2014-02-06
EP3132800A1 (en) 2017-02-22
US20150283200A1 (en) 2015-10-08
CN110090304A (zh) 2019-08-06
US20150157685A1 (en) 2015-06-11
WO2014022552A1 (en) 2014-02-06
US20200000870A1 (en) 2020-01-02
US10201585B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
AU2013296494B2 (en) Methods for treatment of atherosclerosis
Bruna et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice
Lim et al. Proinsulin C-peptide prevents impaired wound healing by activating angiogenesis in diabetes
JP2018203747A (ja) シクロデキストリンを使用するための方法
JP2018203747A5 (cg-RX-API-DMAC7.html)
Zou et al. Resveratrol attenuates pressure Overload‐Induced cardiac fibrosis and diastolic dysfunction via PTEN/AKT/Smad2/3 and NF‐κB signaling pathways
ES2519040T3 (es) Uso de naringenina y de naringina como inhibidores de la ruta de señalización del factor de crecimiento transformante beta1
CN103945840A (zh) 糖尿病性心血管并发症的预防/治疗剂
Akershoek et al. Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds
AU2017345493A1 (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
JP2022537042A (ja) インクレチンミメティックが装填された脂質ナノカプセル
US20100249235A1 (en) Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome
Rodriguiz et al. Combination macrophage-colony stimulating factor and interferon-γ administration ameliorates the osteopetrotic condition in microphthalmic (mi/mi) mice
Zwolak et al. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone
EP0425956A2 (en) ACE inhibitors for use for stabilizing or causing regression of atherosclerosis in coronary arteries
Kusumoto et al. Effect of Statins on Patients With Osteoradionecrosis of the Jaw
Sonwani et al. Simvastatin’s mitochondrial defenses against angiotensin II-induced heart failure
Ogilvie et al. ATYR1923 ameliorates dermal and pulmonary fibrosis in a murine model of sclerodermatous chronic graft vs. host disease
KR102853518B1 (ko) 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제
CN109195596A (zh) 组合物及其使用方法
US20170296499A1 (en) Combinational compositions and methods of use thereof
KR102230271B1 (ko) 지방감소를 위한 글라이코데옥시콜릭산 (Glycodeoxycholic acid, GDCA)를 유효성분으로 포함하는 주사용 제제 및 조성물
KR20070015114A (ko) 3,3,14,14 테트라메틸 헥사데칸 1,16 이산의 투여 방법
KR20220108397A (ko) 아토르바스타틴을 유효성분으로 포함하는 체내 콜레스테롤 합성 저해에 의한골관절염 예방 또는 치료용 약제학적 조성물
CN118743709A (zh) 莫诺苷在制备治疗或预防骨溶解药物中的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: STEALTH BIOTHERAPEUTICS INC.

Free format text: FORMER OWNER(S): STEALTH PEPTIDES INTERNATIONAL, INC.